Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

296

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Schizophrenia
Interventions
DRUG

AZD 8529

40mg oral daily capsule administered as a single dose in the morning for 28 days

DRUG

Risperidone

4mg (2mg on Day 1) oral daily capsule administered as a single dose in the evening for 28 days

DRUG

Placebo to match AZD8529

Placebo to match AZD8529 administered as a daily capsule in the morning for 28 days during the treatment period and also during the 3-7 day washout or run-in period

DRUG

Placebo to match risperidone

Placebo to match risperidone administered as a daily capsule in the evening for 28 days during the treatment period and also during the 3-7 day washout or run-in period

Trial Locations (3)

Unknown

Research Site, Garden Grove

Research Site, Glendale

Research Site, Rockville

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY